ArticleContraception and reproductive medicine2025
Ovario-protective effect of intra-ovarian injection of platelet rich plasma (PRP) after laparoscopic cystectomy of ovarian endometrioma: a randomized control trial.
Article in Contraception and reproductive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Whole ovary cryopreservation and transplantation: a narrative review of technological advances, biological hurdles, and clinical translation in fertility preservation.Journal of assisted reproduction and genetics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the effectiveness of Platelet-Rich Plasma (PRP) in preserving ovarian reserve in patients with endometriosis who underwent laparoscopic cystectomy.
methodA randomized, parallel, open-label phase II clinical trial was conducted. A total of 38 eligible women aged 20 to 35 years with ovarian endometrioma, candidates for laparoscopic ovarian cystectomy, were randomly assigned to either the PRP group (n = 20) or the control group (n = 18). The PRP group received an intra-ovarian injection of 2-4 cc of PRP immediately after cystectomy, while the control group underwent cystectomy without additional intervention. The primary outcome was the change in serum anti-Müllerian hormone (AMH) levels six months post-intervention. The secondary outcome was the antral follicle count (AFC) six months post-intervention. Short-term adverse effects were monitored within the first 48 h after the procedure.
resultsThe PRP group showed a negligible change in AMH levels (mean difference 0.05, 95% CI: -0.17 to 0.26), while the control group exhibited a significant decline (mean difference - 0.24, 95% CI: -0.5 to 0.12). The adjusted mean difference between the groups was - 0.308 (-0.626 to -0.01), tending toward statistical significance (P = 0.057). No significant differences in AFC were observed between the groups, and no short-term adverse events were reported.
conclusionsThis phase II exploratory trial found a near-significant trend toward preservation of AMH levels with intra-ovarian PRP injection after endometrioma surgery. While these findings are not definitive, they support the feasibility and safety of the approach and warrant further evaluation in larger, controlled trials.
trial registrationThe study was prospectively registered in the Iranian Registry of Clinical Trials under the number IRCT20191123045476N3 on December 1, 2021 ( https://irct.behdasht.gov.ir/trial/58688 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.